Tag

en US- Pagina 365

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer

giovedì, 9 Aprile 2026
SHANGHAI, April 9, 2026 /PRNewswire/ — DualityBio (“DualityBio” or the “Company”, Stock Code: 9606.HK) today announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (“ADC”) trastuzumab pamirtecan (“T-Pam”, also

MARKING MAJOR MILESTONE OF 100,000 PATIENTS TREATED, NORDIC PHARMA, INC. (U.S.) ENHANCES ITS OFFERING AND INCREASES PROVIDER CONVENIENCE BY INCLUDING CANNULAS WITH ITS SHIPMENTS OF LACRIFILL® CANALICULAR GEL FOR TREATMENT OF DRY EYE SYMPTOMS

giovedì, 9 Aprile 2026
Nordic Pharma, Inc. is demonstrating this novel therapy at ASCRS  BERWYN, Pa., April 9, 2026 /PRNewswire/ — Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces that it is now shipping cannulas

MARKING MAJOR MILESTONE OF 100,000 PATIENTS TREATED, NORDIC PHARMA, INC. (U.S.) ENHANCES ITS OFFERING AND INCREASES PROVIDER CONVENIENCE BY INCLUDING CANNULAS WITH ITS SHIPMENTS OF LACRIFILL® CANALICULAR GEL FOR TREATMENT OF DRY EYE SYMPTOMS

giovedì, 9 Aprile 2026
Nordic Pharma, Inc. is demonstrating this novel therapy at ASCRS  BERWYN, Pa., April 9, 2026 /PRNewswire/ — Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., announces that it is now shipping cannulas